Can cool dialysate alleviate restless leg syndrome in hemodialysis patients?

Sir,

Restless leg syndrome (RLS) highly affects hemodialysis patients, with a prevalence ranging from 20% to 80%. The most comprehensive RLS theories consider the syndrome to be associated with idiopathic, peripheral neuropathy, dopaminergic system dysfunction, and diminished iron reserves in particular cerebral spots. Calcium–phosphorous imbalance can also play roles in the incidence of RLS.[1]

Basic RLS treatment in hemodialysis patients is the special care, prescribed medications and kidney transplantation; common medications include dopamine agonists, which decrease its severity but are considered as optional treatments. Other medications are anticonvulsants, alpha-2 adrenergic agonists, iron salts, glucocorticosteroids, and benzodiazepines.[2] Since medications bring financial costs for governments and are associated with side effects, specialized care is preferred in alleviating RLS symptoms, with nonmedication interventions, for example, simple exercises, stretching body parts, massage, cold and hot showers, acupuncture, as well as transcutaneous electrical nerve stimulation.[3]

Other factors such as anxiety and depression during the treatment process aggravate the condition; it is also alleged to be associated with undesirable complications such as insomnia and adverse effects on the quality of life and general health.[4]

Cool dialysate can increase the quality of hemodialysis by helping eliminate more poisonous substances such as urea and creatinine, as well by minimizing the effect of these substances on the peripheral nervous system; this will affect RLS alleviation too. In addition, cool dialysate will lower tiredness and enhance energy by improving patients’ mental and physical states, thereby improving their sleeping quality and lowering RLS symptoms. Furthermore, earlier studies argument that by lowering patients’ anxiety and secondary depression, cool dialysate will increase their energy and good feeling, leading to lowered neuropathy.[5] In addition, a thermal exchange will occur between blood and cool dialysate solution (temperature around 35.5°C); this will prevent body temperature from rising. Hemodialysis patients who are usually hypothermic gain heat during hemodialysis; also, they experience vascular constriction.

Cool dialysate based on using 35.5°C dialysis solutions brings about a balanced thermal exchange between blood and hemodialysis solution which prevents vasodilatation and maintains the body temperature stability. Other advantages may include enhanced comfort, lowered tiredness, and refreshed energy during dialysis.[8] Therefore, cool dialysate can enhance the removal of toxic substances such as urea and creatinine, leading to minimized effects on the peripheral nervous system. On dialysis, peripheral neuropathy is diminished and RLS is inhibited to some extent. Furthermore, cool dialysate may play a role in controlling RLS by helping patients cope with secondary intradialytic depression and improving sleep.

On the other hand, since no effectively specific medication is advised for RLS and currently used medicines are all associated with side effects, quality of life and the costs of treatments in hemodialysis patients must be seriously taken into account.

Therefore, further research on the effect of cool dialysate on the RLS symptoms in hemodialysis patients is suggested so that if confirmed in research studies, the 35.5°C dialysis procedure can be used as an effective option in relieving RLS symptoms.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

Mostafa Rad, Nematullah Shomoossi1, Zahra Mirhosseini2, Ehsan Kashani
Department of Nursing, School of Nursing and Midwifery, Sabzevar University of Medical Sciences, 1Department of Medicine, School of Medicine, Sabzevar University of Medical Sciences, 2Department of Internal Disease, Sabzevar University of Medical Sciences, Sabzevar, Iran

Address for correspondence: Dr. Mostafa Rad, School of Nursing and Midwifery, Sabzevar University of Medical Sciences, Sabzevar, Iran. E-mail: mostafarad633@yahoo.com

REFERENCES

1. Giannaki CD, Hadjiigeorgiou GM, Karatzaferi C, Pantzaris MC, Stefanidis I, Sakkas GK. Epidemiology, impact, and treatment options of restless legs syndrome in end-stage renal disease patients: An evidence-based review. Kidney Int 2014;85:1275-82.
2. Ekborn K, Ulfberg J. Restless legs syndrome. J Intern Med 2009;266:419-31.
3. Abetz L, Allen R, Follet A, Washburn T, Earley C, Kirsch J, et al. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther 2004;26:925-35.
4. Molnar MZ, Lu JL, Kalantar-Zadeh K, Kovesdy CP. Association of incident restless legs syndrome with outcomes in a large cohort of US veterans. J Sleep Res 2016;25:47-56.

5. Rad M, Jaghouri E, Sharifipour F, Rakhshani MH. The effects of cool dialysate on pruritus status during hemodialysis of patients with chronic renal failure: A controlled randomized clinical trial. Iran Red Crescent Med J 2017;19:e34759.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.